Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in β-thalassemia

References

• Walter PB, Fung EB, Killilea DW, Jiang Q, Hudes M, Madden J, Porter J, Evans P, Vichinsky E, Harmatz P. Oxidative stress and inflammation in iron overloaded patients with β-thalassemia or sickle cell disease. Br J Haematol 2006; 135: 254–263
   PubMed Web of Science ®Google Scholar
• Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol 1998; 11: 127–146
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Origa R, Piga A, Romeo MA, Zhao H, Cnaan A. Survival and complication in thalassemia. Ann NY Acad Sci 2005; 1054: 40–47
   PubMed Web of Science ®Google Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano PD, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–3737
   PubMed Web of Science ®Google Scholar
• Balfour JAB, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999; 58: 553–578
   PubMed Web of Science ®Google Scholar
• Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood 2005; 106: 3242–3250
   PubMed Web of Science ®Google Scholar
• Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489–496
   PubMed Web of Science ®Google Scholar
• Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in thalassemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Safety 2003; 26: 553–584
   PubMed Web of Science ®Google Scholar
• Motekitis RJ, Martell AE. Stabilization of the iron (III) chelates of 1, 2-dimethyl-3-hydroxypyrid-4-ones and related ligands. Inorg Chim Acta 1991; 183: 71–80
   Web of Science ®Google Scholar
• Devanur LD, Neubert H, Hider RC. The Fenton activity of iron (III) in the presence of deferiprone. J Pharm Sci 2008; 97: 1454–1467
   PubMed Web of Science ®Google Scholar
• Winichagoon P, Fucharoen S, Chen P, Wasi P. Genetic factors affecting clinical severity in β-thalassemia syndromes. J Pediatr Hematol Oncol 2000; 22: 573–580
   PubMed Web of Science ®Google Scholar
• Limenta LMG, Jirasomprasert T, Tankanitlert J, Svasti S, Wilairat P, Chantraraksri U, Fucharoen S, Morales NP. UGT1A6 genetype-related pharmacokinetics of deferiprone (L1) in healthy volunteers. Br J Clin Pharmacol 2008; 65: 908–916
   PubMed Web of Science ®Google Scholar
• Jittangprasert P, Wilairat P, Pootrakul P. Comparison of colorimetry and electrothermal atomic absorption spectroscopy for the quantification of non-transferrin bound iron in human sera. Southeast Asia J Trop Med Public Health 2004; 35: 1039–1044
   PubMedGoogle Scholar
• Janzen EG, Jandrisits LT, Shetty RV, Haire DL, Hilborn JW. Synthesis and purification of 5,5-dimethyl-1-pyrroline-N-oxide for biological applications. Chem Biol Interact 1989; 70: 167–172
   PubMed Web of Science ®Google Scholar
• International Committee for Standardization in Hematology (ICSH). Recommendations for measurement for total and unsaturated iron binding capacity in serum. Br J Haematol 1978;38:281–287.
   PubMed Web of Science ®Google Scholar
• International Committee for Standardization in Hematology (ICSH). Recommendations for measurement of serum iron in human blood. Br J Haematol 1978;38:291–294.
   PubMed Web of Science ®Google Scholar
• Laroff GP, Fessenden RW, Schuler RH. The electron spin resonance spectra of radical intermediates in the oxidation of ascorbic acid and related substances. J Am Chem Soc 1972; 94: 9062–9080
   PubMed Web of Science ®Google Scholar
• Nishi J, Ogura R, Sugiyama M, Hidaka T, Kohno M. Involvement of active oxygen in lipid peroxide radical reaction of epidermal homogenate following ultraviolet light exposure. J Invest Dematol 1991; 97: 115–119
   PubMed Web of Science ®Google Scholar
• Cragg L, Hebbel RP, Miller W, Solovey A, Selby S, Enright H. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998; 92: 632–638
   PubMed Web of Science ®Google Scholar
• Dean RT, Nicholson P. The action of nine chelators on iron dependent radical damage. Free Radic Res 1994; 20: 83–101
   PubMed Web of Science ®Google Scholar
• Morel I, Sergent O, Cogrel P, Lescoat G, Pasdeloup N, Brissot P, Cillard P, Cillard J. EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron loaded hepatocyte culture: comparison with that of deferrioxamine. Free Radic Biol Med 1995; 18: 303–310
   PubMed Web of Science ®Google Scholar
• Matthews AJ, Vercellotti GM, Menchaca HJ, Bloch PH, van Michalek N, Marker PH, Murar J, Buchwald H. Iron and atherosclerosis: Inhibition by iron chelator deferiprone (L1). J Surg Res 1997; 73: 35–50
   PubMed Web of Science ®Google Scholar
• van der Kraaij AM, van Eijk HG, Koster JF. Prevention of postischemic cardiac injury by the orally active iron chelator 1, 2-dimethyl-3-hydroxy-4-pyridone (L1) and the antioxidant (+)-cyanidanol-3. Circulation 1989; 80: 158–164
   PubMed Web of Science ®Google Scholar
• Buettner GR, Jukiewicz BA. Ascorbate free radical as a marker of oxidative stress. An EPR study. Free Radic Biol Med 1993; 14: 49–55
   PubMed Web of Science ®Google Scholar
• Buettner GR. Ascorbate oxidation: UV absorbance of ascorbate and ESR spectroscopy of ascorbyl radical as assays for iron. Free Radic Res Commun 1990; 10: 5–9
   PubMed Web of Science ®Google Scholar
• Buettner GR. In the absence of catalytic metals ascorbate does not autooxidize at pH 7: ascorbate as a test for catalytic metals. J Biochem Biophys Methods 1988; 16: 27–40
   PubMedGoogle Scholar
• Pietri S, Seguin JR, D'Arbigny P, Culcasi M. Ascorbyl free radical: a noninvasive marker of oxidative stress in human open-heart surgery. Free Radic Biol Med 1994; 16: 523–528
   PubMed Web of Science ®Google Scholar
• Buettner GR, Chamulitrat W. The catalytic activity of iron in synovial fluid as monitored by the ascorbate free radical. Free Radic Biol Med 1990; 8: 55–56
   PubMed Web of Science ®Google Scholar
• Morales NP, Chalermchoung C, Fucharoen S, Chantharaksri U. Paraoxonase and platelet-activating factor acetylhydrolase activities in lipoproteins of β-thalassemia/hemoglobin E patients. Clin Chem Lab Med 2007; 45: 884–889
   PubMed Web of Science ®Google Scholar
• Luechapudiporn R, Morales NP, Fucharoen S, Chantharaksri U. The reduction of cholesteryl linoleate in lipoproteins; an index of clinical severity in β-thalassemia/Hb E. Clin Chem Lab Med 2006; 44: 574–581
   PubMed Web of Science ®Google Scholar
• Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 2003; 23: 185–192
   Google Scholar
• Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 2003; 102: 2670–2677
   PubMed Web of Science ®Google Scholar
• Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded β-thalassemia/Hb E patients treated with an oral chelator. Blood 2004; 104: 1504–1510
   PubMed Web of Science ®Google Scholar
• Phumala N, Porasuphatana S, Unchern S, Pootrakul P, Fucharoen S, Chantharaksri U. Hemin: A possible cause of oxidative stress in blood circulation of β-thalassemia/hemoglobin E disease. Free Radic Res 2003; 37: 129–135
   PubMed Web of Science ®Google Scholar
• Mason RP, Fischer V. Possible role of free radical formation in drug-induced agranulocytosis. Drug Saf 1992; 7(Suppl 1)45–50
   PubMedGoogle Scholar
• Berkovitch M, Laxer RM, Inman R, Koren G, Pritzker KP, Fritzler MJ, Olivieri NF. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343: 1471–1472
   PubMed Web of Science ®Google Scholar